BA3011
mAbexperimentalADC
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2018 (NCT03425279)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Fibrosarcoma · Phase 1/Phase 2
- Leiomyosarcoma · Phase 1/Phase 2
- Liposarcoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Sarcoma · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Sarcoma, Synovial · Phase 1/Phase 2
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04918186 | Phase 2 | Oct 12, 2021 | AstraZeneca, BioAtla, LLC, British Columbia Cancer Agency, Canadian Cancer Trials Group, Cancer Research Institute, University of Toronto |
| NCT04681131 | Phase 2 | Dec 31, 2020 | BioAtla, LLC |
| NCT03425279 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2018 | BioAtla, LLC |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioAtla, LLC | For profit | 3 | 2 | 1 | 2018 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2021 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1